Investors

Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.
Recent NewsMore >>
DateTitle 
Dec 12, 2017Geron Reports Imetelstat Presentations at American Society of Hematology Annual MeetingPrinter Friendly Version
Dec 6, 2017Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017Printer Friendly Version
Nov 20, 2017Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic SyndromesPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Corporate Presentation
Download Documentation Post ASH Investor & Analyst Event
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$1.91
Change (%) Stock is Down 0.08 (4.02%)
Volume1,607,882
Data as of Jan 18, 2018 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Contact Information

Anna Krassowska, Ph.D.
E-mail: investor@geron.com

 Print Page |  E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts